CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Sumanta K. Pal,Laurence Albiges,Cristina Suarez Rodriguez,Bo Liu,Jennifer Doss,Sudha Khurana,Christian Scheffold,Martin H. Voss,Toni K. Choueiri

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

2021

Sumanta K. Pal
Laurence Albiges
Cristina Suarez Rodriguez
Bo Liu
Jennifer Doss
Sudha Khurana
Christian Scheffold
Martin H. Voss
Toni K. Choueiri

TPS370Background: Combining anti-angiogenic drugs with immune checkpoint inhibitors (ICI) after progression on ICIs presents a promising therapeutic approach in renal cell carcinoma (RCC). Atezoliz...

Keywords:

Atezolizumab
Cancer research
Therapeutic approach
Cabozantinib
immune checkpoint inhibitors
in patient
Renal cell carcinoma
Medicine
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations